Quarterly report · Q2
2342.TEDINET S100S7OP
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥11.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥89m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥135m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥95m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥199m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥204m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥94m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥157m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥48m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥410m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥55m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥42m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥55m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥10.5bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥366m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥696m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥129m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥216m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥601m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥47m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥485m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥65m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥2.87 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.76 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.32 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.26 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 57.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 32
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥450,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥108m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥981m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥978m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥27m |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥628,000 |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥223m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥196m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥2m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥111m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥153m |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥187,000 |
| jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments into time deposits inv cf | Prior1YTDDuration | -9000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -1500000 | JPY |
| Proceeds from redemption of securities inv cf | Prior1YTDDuration | 5951000 | JPY |
| Proceeds from redemption of securities inv cf | CurrentYTDDuration | － | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -152271000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -109795000 | JPY |
| Payments for investments in capital inv cf | Prior1YTDDuration | － | JPY |
| Payments for investments in capital inv cf | CurrentYTDDuration | -8000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | -692193000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | － | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 94733000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | － | JPY |
| Proceeds from cancellation of insurance funds inv cf | Prior1YTDDuration | 155376000 | JPY |
| Proceeds from cancellation of insurance funds inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | -3410000 | JPY |
| Other net inv cf | CurrentYTDDuration | -9812000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -600814000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -129107000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -7000000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -7000000 | JPY |
| Increase decrease in short term loans payable fin cf | Prior1YTDDuration | 400000000 | JPY |
| Increase decrease in short term loans payable fin cf | CurrentYTDDuration | 320000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -212919000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -260145000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -8560000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -8636000 | JPY |
| Payments for long term accounts payable other fin cf | Prior1YTDDuration | -8067000 | JPY |
| Payments for long term accounts payable other fin cf | CurrentYTDDuration | -8067000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -98531000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -82924000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 64920000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -46774000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 7852000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 2742000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -1223856000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -538686000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4618521000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3459447000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3394665000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 2920760000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 229305000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 249505000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 2133000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 2523000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 28372000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 32008000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 1265404000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 4275889000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 5541293000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | 1050000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |